International business has become a key performance driver. Mindray generated RMB 8.33 billion in overseas revenue, accounting for 49.77% of its total, up 5.39% year-on-year. Assure Tech and Alltest reported over 90% of revenue from abroad, while Cowin Biotech grew overseas revenue 40.83%.

Profitability among IVD companies diverged sharply. Mindray led with a net profit of RMB 5.069 billion in H1 2025, followed by Andon Health (RMB 920 million) and Snibe (RMB 771 million).

Nineteen companies reported R&D-to-revenue ratios above 20% in H1 2025. Roughly 42.5% of IVD companies increased their R&D spending compared to revenue.

As of August 31, 2025, China has 83 publicly listed companies related to in vitro diagnostics (IVD), including 62 whose core business is IVD and 21 with IVD-related operations. Among the 62 core IVD companies, 59 have disclosed their 2025 half-year reports.

Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended June 30, 2025.

The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on September 3, under the chairmanship of Alexandre Mérieux and approved the consolidated financial statements for the six months ended June 30, 2025.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

MGI Tech has reported that its revenues for the first half of 2025 dropped 8 percent year over year, mainly due to declining instrument sales.

Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.74 billion for the third quarter ended July 31, 2025, exceeding revenue guidance and representing growth of 10.1% reported and up 6.1% core(1) compared with the third quarter of 2024.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.